Aura Biosciences is a clinical-stage biotechnology company that designs an oncology platform for the delivery of drugs targeting cancer indications, focusing on ocular and urologic oncology. Its NanoSmart drug delivery system encapsulates therapies within protein nanoparticles. The company also develops virus-like drug conjugates (VDCs) such as AU-011 for the first-line treatment of primary choroidal melanoma.